Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
Post-marketing Commitment Safety Study of HZ/su to Evaluate Pregnancy Exposures and Outcomes in Immunodeficient or Immunosuppressed Women Between 18 and 49 Years of Age
Sponsor: GlaxoSmithKline
A observational or N/A phase clinical study on Herpes Zoster, this trial is ongoing. The trial is conducted by GlaxoSmithKline and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2025 [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
May 2023 — Jul 2024 [monthly]
Not Yet Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Harvard Pilgrim Health Care Institute
For direct contact, visit the study record on ClinicalTrials.gov .